<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01139138</url>
  </required_header>
  <id_info>
    <org_study_id>AU-2009-0003/CRAD001CAU06T</org_study_id>
    <nct_id>NCT01139138</nct_id>
  </id_info>
  <brief_title>Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer</brief_title>
  <acronym>PIE</acronym>
  <official_title>A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Queen Elizabeth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Queen Elizabeth Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety of panitumumab, irinotecan and everolimus when given in&#xD;
      combination to treat advanced colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label uncontrolled phase IB/II study to determine the maximum tolerated dose&#xD;
      (MTD) and assess the efficacy of everolimus, irinotecan and panitumumab when given in&#xD;
      combination for patients with metastatic colorectal cancer and KRAS wild-type (WT). Patients&#xD;
      with metastatic colorectal cancer (mCRC) that have failed fluorouracil based first line&#xD;
      therapy will be included. It is anticipated that approximately 50 patients will be enrolled&#xD;
      over a period of 24 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>at end of cycle 2 (each cycle is 14 days)</time_frame>
    <description>To determine the maximum tolerated dose (MTD)of everolimus, irinotecan and panitumumab when given in combination for patients with Kras WT mCRC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; toxicity</measure>
    <time_frame>Approximately 24 weeks</time_frame>
    <description>Safety and toxicity assessed weekly during the phase Ib component (as per NCI CTCAE version 3.0) and fortnightly during the phase II component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Assessed every 6 weeks until disease progression</time_frame>
    <description>Objective tumour response as per RECIST criteria V1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Until disease progression, occurrence of new disease or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Assessed 3 monthly until death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Colorectal Tumors</condition>
  <condition>Neoplasms, Colorectal</condition>
  <arm_group>
    <arm_group_label>Panitumumab + Irinotecan + Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 6mg/kg IV every 14 days</description>
    <arm_group_label>Panitumumab + Irinotecan + Everolimus</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 200mg/m2 IV every 14 days</description>
    <arm_group_label>Panitumumab + Irinotecan + Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus daily po (dosage varies with cohort)</description>
    <arm_group_label>Panitumumab + Irinotecan + Everolimus</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Histological diagnosis of colorectal cancer that is KRAS wild type&#xD;
&#xD;
          -  Metastatic disease not amenable to resection&#xD;
&#xD;
          -  Measurable disease as assessed by CT scan using RECIST criteria&#xD;
&#xD;
          -  Received and failed fluoropyrimidine therapy&#xD;
&#xD;
          -  Radiographically documented disease progression per RECIST criteria&#xD;
&#xD;
          -  For phase 1b group only, ECOG PS 0-1&#xD;
&#xD;
          -  For phase 2 group only, ECOG PS 0-2&#xD;
&#xD;
          -  Adequate bone marrow function with haemoglobin &gt; 100 g/L, platelets &gt; 100 X 109/l;&#xD;
             neutrophils &gt; 1.5 X 109/l within 7 days of enrolment&#xD;
&#xD;
          -  Adequate renal function, with calculated creatinine clearance &gt;40 ml/min (Cockcroft&#xD;
             and Gault) within 7 days of enrolment&#xD;
&#xD;
          -  Adequate hepatic function with serum total bilirubin &lt; 1.25 X upper limit of normal&#xD;
             range and ALT or AST&lt;2.5xULN (&lt;5xULN if liver metastases present) within 7 days of&#xD;
             enrolment&#xD;
&#xD;
          -  Magnesium ≥ lower limit of normal within 7 days of enrolment.&#xD;
&#xD;
          -  Fasting serum cholesterol ≤ 7.75mmol/L AND fasting triglycerides ≤ 2.5 x ULN. Note: In&#xD;
             case one or both of these thresholds are exceeded, the patient can only be included&#xD;
             after initiation of appropriate lipid lowering medication.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Negative pregnancy test ≤ 72 hours before commencing study treatment (women of&#xD;
             childbearing potential only).&#xD;
&#xD;
          -  Written informed consent including consent for biomarker studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of KRAS mutation in tumour sample&#xD;
&#xD;
          -  For Phase 1b group only, patients with prior pelvic radiotherapy.&#xD;
&#xD;
          -  Systemic chemotherapy, immunotherapy, approved proteins/antibodies or any&#xD;
             investigational agent within 4 weeks prior to commencing study treatment&#xD;
&#xD;
          -  Radiotherapy within 14 days of commencing study treatment.&#xD;
&#xD;
          -  Unresolved toxicities from prior systemic therapy or radiotherapy&#xD;
&#xD;
          -  Medical or psychiatric conditions that compromise the patient's ability to give&#xD;
             informed consent or to complete the protocol&#xD;
&#xD;
          -  Prior treatment with drugs targeting EGFR such as cetuximab, panitumumab or erlotinib&#xD;
&#xD;
          -  Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus)&#xD;
&#xD;
          -  Prior therapy with irinotecan&#xD;
&#xD;
          -  CYP3A4 enzyme inducing anti-convulsant medication ≤ 14 days prior to study treatment.&#xD;
&#xD;
          -  Ketoconazole ≤ 7 days before study treatment.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus defined by fasting glucose &gt;1.5 x ULN.&#xD;
&#xD;
          -  Known cirrhosis, chronic active hepatitis, or chronic persistent hepatitis&#xD;
&#xD;
          -  Patients with known interstitial lung disease or severely impaired lung function&#xD;
&#xD;
          -  Patients with active bleeding diatheses.&#xD;
&#xD;
          -  Any uncontrolled clinically significant cardiac disease, arrhythmias or angina&#xD;
             pectoris&#xD;
&#xD;
          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea&#xD;
&#xD;
          -  Chronic treatment with immunosuppressives&#xD;
&#xD;
          -  Patients with a known history of HIV seropositivity&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions or infections&#xD;
&#xD;
          -  Untreated or symptomatic CNS metastases&#xD;
&#xD;
          -  Patients who have a history of another primary malignant disease&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Women and partners of women of childbearing potential who are not using effective&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Townsend, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Queen Elizabeth Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2010</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Queen Elizabeth Hospital</investigator_affiliation>
    <investigator_full_name>Amanda Townsend</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Colorectal Carcinoma</keyword>
  <keyword>Colorectal Tumors</keyword>
  <keyword>Neoplasms, Colorectal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

